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Abstract
Objective—Essential hypertension (EH) is the most common chronic disease in the United 
States and a major cause of morbidity and mortality. Lifestyle interventions (e.g., diet, exercise, 
stress management) to reduce blood pressure (BP) are often complex with varying effectiveness. 
Breathing awareness meditation (BAM) is a stress management strategy with encouraging effects 
on BP, though widespread dissemination is hampered by the lack of an easy-to-use methodology 
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to train and monitor BAM practices. A smartphone application (Tension Tamer, TT) that 
implements BAM and tracks adherence has shown promise in addressing these gaps. This 6-month 
dose-response feasibility trial evaluated effects of the app on BP to further optimize BAM user 
guidelines.
Methods—Sixty-four adults with pre-hypertension were randomized to complete TT-guided 
BAM sessions for 5-, 10-, or 15-minute intervals twice daily over 6 months. Continuous heart rate 
readings derived from the phone’s video camera via reflective photoplethysmography were used as 
feedback and as an index of time-stamped adherence. Outcomes (resting BP, HR) were collected at 
baseline, 1-, 3-, and 6-months.
Results—Mixed modeling results showed a significant time effect for systolic BP (SBP) with a 
dose-response effect at months 3 and 6. Adherence declined over time and was lowest in the 15-
minute dose condition, though SBP reductions were maintained. Generally, adherence was 
negatively associated with dose as the study progressed.
Conclusions—Smartphone-implemented BAM appears to reduce SBP and can be a low cost 
method to reach large populations.
Keywords
essential hypertension; blood pressure; breathing meditation; mobile health; smartphone 
application
Essential hypertension (EH) is the most common chronic disease in the United States 
impacting approximately one third of adults. EH is a primary risk factor for stroke, 
myocardial infarction, heart disease, chronic kidney disease and retinopathy (Go et al., 2014; 
Guo, He, Zhang, & Walton, 2012; Kannel, Vasan, & Levy, 2003). EH results from a 
complex interplay between an individual’s genetic predisposition, lifestyle behaviors, and 
exposures to various environmental toxins culminating in disease (Imumorin et al., 2005; 
Kurland, Lind, & Melhus, 2005; Lewontin, 2001). Chronic stress (e.g., repeated exposures 
to discrimination, family dysfunction, marital/relationship discord, financial strain, job 
strain, etc.) is a key environmental factor that has been implicated in development of EH 
(Esler et al., 2008; Rutledge & Hogan, 2002; Spruill, 2010; Tennant, 2001) and a target for 
preventive interventions.
Stress Reduction Treatments for EH
Evidence that chronic stress exposure contributes to EH and cardiovascular disease has 
resulted in a plethora of behavioral mind–body stress reduction programs, including various 
forms of meditation. Meditation is an empirically supported stress reduction technique. The 
quality of research designs to investigate these programs’ effects upon BP varies and studies 
have shown mixed results, but overall findings trend toward a positive effect (Büssing, 
Michalsen, Khalsa, Telles, & Sherman, 2012; Cohen & Townsend, 2007; Dickinson et al., 
2008; Okonta, 2012; Rainforth et al., 2007). In one review of 20 RCTs, Transcendental 
Meditation® (TM) was the only treatment to significantly reduce BP (average systolic BP 
(SBP) reduction = −5.5 mmHg), with effects comparable to more complicated and 
demanding lifestyle programs (e.g., diet, physical activity) (Dickinson et al., 2006; Rainforth 
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et al., 2007). Although useful in reducing BP, the financial costs and training demands (i.e., 
multiple sessions with certified instructor) of TM limits its scalability. The easy to learn and 
virtually cost-free nature of breathing awareness meditation (BAM) – a basic form of 
mindfulness meditation – makes it a promising alternative to TM (Goldsetin, Josephson, 
Xie, & Hughes, 2012). In BAM, practitioners engage in slow, diaphragmatic breathing while 
attending to breathing sensations in the body. Unlike TM, mantras are not used and training 
does not require special certification; BAM can be learned quickly and via a variety of 
modalities including books, online tutorials, videos, and in-person instruction. RCTs in 
adults with preEH and EH who used BAM 10 minutes, twice daily for 3 months resulted in 
SBP reductions of −4.3 and −7.2 mmHg, supporting its potential efficacy as a non-
pharmacologic adjunct BP reduction therapy (Mourya, Mahajan, Singh, & Jain, 2009; Wang 
et al., 2010). BAM is also a foundational component of mindfulness-based stress reduction 
(MBSR), which has been shown to reduce SBP in adults with preEH (Hughes et al., 2013).
Critical Gaps in Meditation BP Control Research
Despite promising findings for TM and BAM, several critical gaps remain regarding 
meditation’s impact on BP prior to addressing its potential in the prevention/delay of EH 
onset and as an adjunct therapy for EH management. First, few RCTs have involved at-risk 
adults with preEH (for reviews see: (Anderson, Liu, & Kryscio, 2008; Ospina et al., 2007; 
Rainforth et al., 2007)). SBP and diastolic BP (DBP) levels are monotonically associated 
with future development of cardiovascular morbidity and mortality (Kannel et al., 2003). 
Adults with stage 1 preEH (i.e., SBP/DBP 120-129/80-84 mmHg) have a 40% increased 
risk, and those with stage 2 preEH (SBP/DBP 130-139/85-89 mmHg) have twice the risk of 
developing EH compared to those with optimal BP levels (<120/<80 mmHg;(Kannel et al., 
2003)). Second, RCT-evaluated meditation programs have typically involved multiple 
individual and/or group training and follow-up sessions, limiting reach and scalability. 
Third, there has been a lack of objective adherence measurements where non-instructor 
observed sessions have been based upon self-report (e.g., journaling, retrospective 
reporting). True dosage received is unknown and may partially account for heterogeneity in 
individuals’ BP changes within and across meditation RCTs (Barnes, Gregoski, Tingen, & 
Treiber, 2010; Barnes, Pendergrast, Harshfield, & Treiber, 2008; Barnes, Treiber, & 
Johnson, 2004; Gregoski et al., 2012; Nidich et al., 2009; Ospina et al., 2007; Rainforth et 
al., 2007; Wright, Gregoski, Tingen, Barnes, & Treiber, 2011). TM and BAM studies have 
typically prescribed twice daily sessions of 10- or 20-minute durations each, but a dose-
response evaluation has never been conducted. It is unknown whether, for instance, 10 vs. 20 
vs. 30 minutes/day will have graded responses upon BP or which regimen would yield the 
best patient adherence. These questions are critical when developing evidence-based 
guidelines for delivery of BAM in clinical contexts.
Tension Tamer: A Smart Phone BAM Application (App)
One solution to address these gaps in existing meditation programs is to develop, rigorously 
test, and refine a smartphone app designed to deliver BAM. Smartphone apps for preventive 
medicine and chronic disease management hold great promise in terms of reach for 
widespread dissemination. Their portability also increases capacity for users to engage in 
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BAM at times and in places that are most convenient to them. In 2016, 77% of adults in the 
U.S. owned smartphones (up from 35% in 2011), irrespective of race/ethnicity, 
socioeconomic status or geographical location (Poushter, 2016; Smith, 2015), and rates 
continue to rise steadily. There also is substantial public interest in meditation – and use of 
meditation smartphone apps, specifically – as a complementary and alternative approach to 
BP and stress management as evidenced by the millions of U.S. adults who practice 
meditation (Cramer et al., 2016) or who have downloaded commercial meditation apps (e.g., 
Birkner, 2016; Weiczner, 2017). Despite a proliferation of apps purporting to provide 
training in mindfulness meditation, there is little published evidence about their impact on 
targeted health outcomes (Mani et al., 2015).
Tension Tamer (TT) smartphone BAM app was developed using a patient-centered iterative 
design approach guided by behavioral change and technology utilization theories. 
Behavioral content and implementation formats were guided by theoretical constructs in the 
self-determination (Ryan & Deci, 2000) and social cognitive theories (Bandura, 2001), 
which posit that fostering self-efficacy, competence, and autonomous regulation (i.e., 
intrinsic motivation) for the desired behavior changes are critical for initial engagement and 
sustaining adherence over time. The People, Activity, Context and Technology Approach 
(PACT) has guided prior development of TT usability and posits users must feel at ease with 
and perceive the technology as useful in reaching a desired goal (Beynon-Davies & Holmes, 
2002). It is expected that, over time, with positive feedback (including immediate HR 
feedback charts, reinforcement and motivational text messages), self-efficacy, autonomous 
regulation, internalization, and integration will occur, leading to adoption and maintenance 
of BAM for stress reduction and BP management.
Promising results were observed in a 3-month proof-of-concept study where 3 pre-EH adult 
participants completed twice daily 10-minute BAM sessions via TT on an Android phone 
(Gregoski, Vertegel, Shaporev, & Treiber, 2013). Participants received a feedback chart of 
average HR/minute and maximum decline immediately after each session. Motivational and 
social reinforcement text messages were sent based upon the previous day’s adherence 
levels. Clinically relevant BP decreases from pre- to post-intervention were observed in 
resting (−8.8 mmHg) and ambulatory (e.g., −3.7 mmHg for 24-hr; −4.3 mmHg for daytime) 
SBP (Gregoski, Sieverdes, et al., 2013). Time stamped HR signal transmission to the server 
indicated participants’ average adherence rates by month were 74.9%, 76.9% and 75.9%, 
supporting use of the HR data as a measure of engagement.
Additional user input guided content and implementation format refinement, including 
background image content and themes. Four focus groups of adults with preEH (total n=34) 
were conducted to guide refinement of TT’s training content, experience, and user feedback. 
Participants gained hands-on experience using a demo version of TT on smartphones then 
reported on perceived usability and preferences for use, features, and graphical feedback. 
They also reported a strong preference for participating in BAM via smartphone app rather 
than face-to-face instruction, with 66% of participants indicating they would be unwilling to 
participate in a trial where they may be randomized to in-person, clinic-based BAM 
instruction rather than smartphone-delivered BAM. These findings underscore the potential 
for large-scale adoption for app-based BAM interventions.
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Dosage requirements of BAM delivered via the TT app to emphasize optimal adherence 
usage and changes in BP to prevent EH are still unknown and are the focus of this study. 
Dose-response efficacy outcomes are needed to inform investigators of the optimal treatment 
strategy in the development of a large-scale efficacy RCT using mHealth BAM approaches. 
Therefore, this study reports the feasibility outcomes (i.e., adherence, duration) and dose-
response effects of a 6-month mHealth BAM intervention conducted with adults with preEH 
randomized to twice a day 5-, 10-, and 15-minute dosage conditions. Results will provide 
insight into the BAM dosage that strikes an optimal balance of participant adherence and 
beneficial effects in reducing the primary outcome SBP.
Method
Participants
Adults (N=287) were recruited by flyers and clinic referral from a southeastern US costal 
city (population approximately 120,000). Potential subjects either contacted study personnel 
or were contacted via phone to determine eligibility and interest in participation. Inclusion 
criteria were (1) ≥21years of age, (2) Non-Hispanic White or African American (in keeping 
with formative work), and (3) preEH (i.e., SBP 121-139 mmHg on 3 consecutive occasions). 
Exclusion criteria included: (1) unwillingness to accept randomization into one of three 
dosage groups, (2) any chronic disease or medical condition that required regular 
pharmacological intervention or use of medications that may affect BP, (4) inability to use a 
smartphone (e.g., unable to open and navigate the app even after in-person instruction; 
inability to operate smartphone or hold finger to camera due to excessive tremor; inability to 
see content; etc.), (5) pregnant, lactating or intention of becoming pregnant during the trial, 
(6) participant in another study, (7) inability to speak, hear, or understand English, and (8) 
poor home cellular coverage.
Of the 287 candidates, 223 were excluded, most commonly due to BP being below the 
preEH range (n = 155; see Figure 1). The remaining 64 eligible candidates consented to 
participate in the dose response trial and provided baseline data. Two participants withdrew 
before or within the first month due to loss of interest or daily schedule conflicts, and 3 
participants were dropped from analyses due to complete non-adherence in the first 3 weeks. 
For these 5 participants, no follow-up data were available, resulting in a final sample of 59 
participants for follow-up analysis. Withdrawals were evenly distributed across dosage 
conditions. No participants withdrew due to technical issues or inadequate cellular signal.
Procedure
All procedures were approved by the Medical University of South Carolina institutional 
review board (Pro00020894). The study spanned August 2014 to October 2016.
BP screening and enrollment—A trained research assistant screened participants for 
preEH on three separate sessions spaced at least 24 hours apart. Sessions were conducted in 
a quiet, private conference room at the academic medical center. Resting heart rate (HR), 
SBP and diastolic blood pressure (DBP) were recorded from the right arm at heart level, 
while the patient remained in a seated position using a properly sized cuff and the GE 
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Carescape V100 monitor (GE Healthcare, Milwaukee, WI). Readings were recorded at 
minutes 0, 5, and 7. The first measurement was discarded and the last two measurements 
were averaged for a final session reading. Individuals were invited to participate in the 
clinical trial if their average SBP was in the preEH range (i.e., SBP 120-139 mmHg) on all 3 
screening days (Chobanian et al., 2003). After preEH status was confirmed, written 
informed consent was obtained, sociodemographic (age, sex, education, income) and 
anthropometric (height, weight, waist circumference) data were gathered, and the TT 
orientation training was completed. BPs and HR were collected at 1-, 3-, and 6-month 
follow-up appointments using the same clinical laboratory procedures described above. Staff 
who assessed BP and other outcomes were blind to participants’ group assignment.
TT Intervention—During the one-on-one, in-person orientation session, the TT app was 
downloaded to each participant’s personal smartphone (i.e. Android or Apple iPhone). 
Research staff instructed participants in navigating the TT app, then participants completed 
their first BAM session and were provided opportunities to ask questions about the app and 
its functionality before leaving the medical center. All participants successfully completed a 
TT BAM session under staff supervision before taking the app home for daily sessions. 
Participants were randomized to one of three TT dosage conditions (5, 10, or 15 minutes 
twice daily) using a pre-defined randomization table. Dosage conditions were based on prior 
RCTs with input from focus groups of preEH patients during formative stages of this 
research. Participants were told to complete each TT session in a quiet, distraction-free 
place. To start each TT session, participants opened the app, placed their index finger over 
the rear-facing camera of their smartphone, and pressed ‘start’ on the app’s main screen. The 
TT app would verify a stable HR response within 20-30 seconds and then allow initiation of 
the session. A user-selected tone (gong or chime) would notify participants when the 
sessions were over and give vibration feedback if the device could not capture the HR signal 
due to poor connection of fingertip with camera or excessive body movement. The 
instructional session included mandatory use of a recorded voice to guide participants in 
BAM. Following the training session, participants could select whether to keep the audio 
guide during sessions. During each BAM session, participants were directed to sit 
comfortably, close their eyes, and attend to the movement of their diaphragm while 
breathing in a slow, deep, relaxed manner. Participants were given written and audio 
instructions regarding strategies for optimizing BAM practice within the app that could be 
accessed at any time. An on-screen timer was displayed for the duration of each session and 
tones signaled the start and finish of each session. Participants were compensated $145 for 
their time and effort after each of the clinical visits (baseline, 1-mo, 3-mo, 6-mo), 
irrespective of their TT regimen adherence.
TT Adherence—Adherence was operationalized as completion of the two daily TT 
sessions per day. Partial adherence (.5) was allocated to full completion of 1 of 2 assigned 
sessions for the day. Encrypted time stamped HR data measured via built-in 
photoplethysmograph (PPG) from the participant’s TT app were automatically transferred to 
the university’s server infrastructure (Gregoski et al., 2012; Gregoski et al., 2013). These HR 
data were used as objective indices of adherence (i.e., 1.0 adherence indicated the app was 
used across the full dosage duration on two sessions over a 24 hour period with > 5 minutes 
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separation between sessions). Adherence was reported as a monthly percentage calculated as 
the average of the daily adherence scores (0, 0.5, or 1.0) across the number of days in the 
month. When compared with BP changes, adherence value represents the 1-month 
percentages leading up to that study month’s BP measure (i.e. BP month 3 is compared with 
month 3 adherence %). Adherence categories were defined as <75% or ≥ 75% based on 
preliminary studies and other previous meditation RCTs where 75% adherence was 
associated with adequate BP reductions.
TT Accumulated Duration—Duration represents the cumulative monthly total of 
minutes using TT with the estimate calculated as (dose in minutes x 2 sessions per day x 
number of days in the particular month) and categorized by tertiles (0-300 min/month, 
301-600 min/month, 601-900 min/month). Duration of completed sessions was collected by 
the TT app.
Physical Activity—The sweat index measured the number of days per week that activity 
was performed vigorously enough to work up a sweat (i.e., scored 0 days = 1, 1 day = 2,…8 
etc.).
Satisfaction and Usefulness—The Telemedicine Satisfaction and Usefulness 
Questionnaire (TSUQ; Bakken et al., 2006) was administered to participants at the 6-month 
time point. The TSUQ asks participants to rate how satisfied they were with the app, how 
easy it was to use the app, and how easy it was to learn the app. Ratings were made using a 
5-point Likert scale (1=strongly disagree; 5=strongly agree). The percentage of participants 
who provided positive ratings (4 or 5) for satisfaction, ease of use, and ease of learning the 
app were examined.
Statistical Analyses
All BP and HR data were tested for outliers using box-plots and Iglewicz and Hoaglin robust 
tests for multiple outliers (two-sided). Outliers per both conditions (Hoaglin & Iglewicz, 
1987) were excluded to meet assumptions of statistical procedures. The outliers in change 
scores consisted of the following: 2 from SBP-month 1 [+10.0, +9.8 mmHg]; 1 from SBP-
month 3 [+26.8 mmHg]; 1 from DBP-month 1 [+8.0 mmHg]; 1 from DBP-month 3 [+11.5 
mmHg]; 1 from HR-month 1 [−28.2 b/min]; 2 from HR-month 3 [−28.2, −29.3 b/min]. After 
data cleaning, data were tested for normality using Shapiro-Wilk testing.
Demographics were compared by dosage conditions using one-way ANOVA for continuous 
variables and Chi-square tests for categorical variables. Analyses for overall longitudinal 
intervention effects from baseline to follow-up month for SBP, DBP, HR, and adherence 
were performed using mixed modeling using maximum likelihood estimation and fixed 
effects. Further modeling included adjustments for covariates including age, gender, race, 
and physical activity. Physical activity was adjusted for in model 2 with the sweat index 
scale using change scores from baseline to follow-up month. Correlations between SBP and 
adherence and SBP and duration were calculated. Lastly, mean adherence and proportions of 
participants meeting at least 75% of sessions were reported by study month. ANOVA and 
chi-square tests were used to compare across dosage conditions. Significance was evaluated 
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based on p = 0.05. Analyses were carried out using SAS/STAT® software (SAS Institute 
Inc., USA) and IBM SPSS Statistics, Version 24.0 (Armonk, NY: IBM Corp.).
Sample size was determined via a priori power calculations, where primary outcomes were 
% of dosage group reaching 75% adherence target and % of dosage group reaching target 
clinically significant SBP reductions. It was determined that 18 participants randomized to 
each intervention group (total N=54) would result in at least 80% power to detect a 
difference in proportions of each group reaching the 75% adherence target. Similarly, 18 
participants randomized to the three dosage groups was also calculated to give 80% power to 
detect at least a 0.96 sd unit effect size at alpha = .05, two-tailed for continuous adherence 
and SBP measures. Additional participants were recruited to account for potential attrition.
Results
Demographic results
Table 1 displays participant characteristics. Overall mean age of the 64 participants was 34.9 
(SD=12.6) years with nearly equal distribution between genders (52.5% male) and race 
(49.2% African American). Most participants were college educated (54.2%) or had 
completed trade school (16.9%). No demographic variable was significantly different among 
dosage conditions.
Overall BP and HR results
Mixed modeling analyses for overall intervention effects showed significant decreases in 
SBP during all follow-up months for raw and adjusted models (all p-values < .001) (see 
Table 2). Similar changes were found for DBP at month 1 which remained significant at 
month 3 (p = .003) and 6 (p = .034) after adjusting for covariates. Modeling for HR changes 
resulted in mixed findings with p-values ranging between .01 and 0.36 after adjustment. A 
better fit was found in model 1 compared to raw values with lower AICs on all regression 
outputs. Change scores resulted in large effect sizes for SBP at each follow-up visit (average, 
Cohen’s d = 1.13 to 1.80), medium to large effect sizes on DBP (Cohen’s d = 0.70 – 1.12) 
with low effect sizes on HR (Cohen’s d = 0.079-0.67). Of notable importance, paired 
differences in BP measures showed clinically relevant reductions in SBP in months 1-3 
(−9.1 to −8.1 mmHg) with moderately reductions in DBP (−5.8 to −3.4 mmHg).
Dose Response Findings for BP and HR
SBP change scores among categories of TT dose, adherence, and duration between months 
1, 3, and 6 are reported in Table 3. Mixed modeling analysis revealed a significant effect of 
dosage and adherence upon SBP. Generally, greater SBP reductions were observed as dose 
increased. Higher TT dose resulted in greater reductions in SBP at months 3 (p = .015) and 6 
(p = .018), following adjustment for age and gender. Comparisons within month 3 revealed 
differences between the 5-min and 15-min dosages (LSD: p = .022) and the 10-min and 15-
min dosages (LSD: p = .010; Tukey-Kramer: p = .027). Multiple comparisons within month 
6 showed differences between 5-min and 15-min dosage conditions (LSD: p = .007; Tukey-
Kramer: p = .18) (See Figure 2). No significant findings for DBP or HR were observed by 
dosage condition between or within each month.
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Participants with higher adherence at month 1 demonstrated greater reductions in SBP than 
participants with adherence below the 75% cutoff, but no adherence related effects were 
observed at subsequent time points (see Table 3).
Using the duration variable (total min/month), results generally illustrated that as TT use 
duration categories increased, SBP reductions increased, especially in the high duration 
category (601-900 min/month). Within-month differences were found at month 1 (p = .011) 
and remained significant after adjusting for covariates, indicating greater reductions with 
greater TT duration.
Correlations showed a significant, moderate, inverse relationship between SBP change 
scores and adherence at month 1 (r = −0.30 p = .024), and with total duration at month 1 (r = 
−0.38, p = .004). No significant correlations were found at months 3 or 6 (p-values range .
12-.43).
Retention Rates
Initial study withdrawals were similar across dosage condition. Study retention was strong 
across the duration of the study. The 5-minute dosage group experienced a retention rate of 
95% for month 3, and 81% for month 6. The 10-min dosage experienced a retention rate of 
94% for month 3 and 78% for month 6. Lastly, the 15-min dosage group experienced a 
retention rate of 100% for months 3, and 75% for month 3.
Adherence
Mean monthly adherence measures by dose are reported in Table 4a and proportions of 
participants meeting at least 75% of TT sessions are shown in Table 4b. At month 1 there 
were no differences in adherence levels between the 3 dosage groups (p = .91). However, at 
months 2, 3, 5, and 6, the 15-min dosage group was significantly less adherent than the other 
dosage groups (ps < .05). Analyses using a ≥75% adherence criterion revealed significant 
differences between dosage groups in months 2, 3 and 6 (p-values < 0.034) showing the 15-
min group exhibited the lowest proportion of success in months 2 and 6, whereas in month 3 
the 5-min group showed the lowest success rate (though still 60%; see Table 4b). Intention to 
treat analysis (Table 4c) showed similar results but finding a significant difference at month 
6 (p = 0.006) where only 14% in the 15-min dosage group met the 75% adherence criterion 
compared to 57% in the 5-min and 37% in the 10-min condition.
Satisfaction and usefulness
At the 6-month time point, 89% of participants reported high satisfaction,; 94% found the 
app easy to use, and 96% reported it was easy to learn how to use the app.
Discussion
There is need for effective, inexpensive, acceptable interventions that can be widely 
disseminated to reduce the public health burden of EH. This study evaluated TT, a 
smartphone-based app designed to teach and monitor BAM techniques among adults with 
preEH. Statistically significant and clinically relevant reductions in SBP were observed 
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between baseline and evaluations at 1, 3 and 6 months irrespective of dosage conditions. In 
addition, a significant dose-response association was found for SBP at months 3 and 6, with 
the 15-min dosage group showing the greatest reductions.
It appears the first month of intervention is a critical time frame for establishing BAM 
effects upon SBP, given the observed trends across dosage conditions, adherence levels, and 
TT duration (total min/month) over the course of the trial. In initial weeks, users build BAM 
skills that carry across to subsequent time periods. Given first-month adherence was high 
across all dosage conditions, participants in the 15-min dosage group practiced and 
experienced the highest duration of BAM in the first month compared to other groups. 
Indeed, higher duration was found to be associated with greater SBP reduction in the first 
month, and participants in the 15-min condition showed greatest SBP reductions at months 3 
and 6. This suggests it may be valuable to recommend a TT starting dosage of 15-min twice-
daily in the first intervention month intervention to maximize early exposure to BAM 
practice and promote durable SBP reductions.
Results revealed variability in adherence across dosage conditions in later months, which 
potentially masked the association between adherence and SBP changes. The decline in 
adherence among participants in the 15-min dosage condition may have been due to higher 
burden associated with setting aside 30 minutes daily for BAM sessions. The lower dosage 
conditions may have been more easily and conveniently integrated into participants’ daily 
routines, facilitating higher adherence over time. Still, participants in the 15-min dosage 
condition demonstrated greatest SBP reductions over time. Participants assigned to the 15-
min condition may have mastered BAM more rapidly than participants in the other groups, 
rendering adherence to the pre-specified twice-daily sessions less important later in the trial. 
Participants in the 15-min dosage group may have started TT sessions but ended them 
prematurely later in the trial as they became more efficient in achieving stress reduction 
goals or practiced BAM in shorter sessions outside the TT app as part of their routine or in 
response to onset of stress, anxiety, rumination, etc. Engagement in such partial sessions 
where participants did not use the app for the full assigned dosage time would have 
contributed to lower observed adherence rates, despite ongoing consistent use of BAM in 
participants’ daily lives and persistent reductions in SBP for that group. Participants may 
have also used BAM as part of their repertoire of coping mechanisms which may have 
impacted BP and HR during the trial.
Benefits in the form of BP reduction were obtained even at the lowest TT dosage condition. 
Assigning twice daily 5-minute BAM sessions with TT may be sufficient for achieving 
desired clinical outcomes among preEH users even though a larger benefit could be found in 
higher doses. It is unknown if briefer or less frequent BAM sessions may result in similar BP 
reductions and higher adherence. It is also unknown whether more dramatic improvements 
in BP and HR would have been observed with even higher TT dosage conditions. Findings 
from the cumulative duration per month seemingly support the notion that total monthly 
duration may be more important than length of individual sessions, though nearly all the 
highest duration group were from the 15-minute dosage condition. To maximize duration of 
exposure and adherence over time, it may be worthwhile to assign a relatively high dose of 
TT initially followed by a lower dose maintenance regimen to maintain practice.
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In the current trial, clinically meaningful SBP reductions were observed in adults with 
preEH that were observable within 1 month of TT use (range for average SBP reduction 
across dosage: −7.9 to −10.9 mmHg) and maintained up to 6 months post-baseline (range for 
average SBP reduction across dosage: −5.1 to −12.4 mmHg). The magnitude and durability 
of these effects is notable given the intervention was entirely app-based and dosage was as 
low as 10 minutes per day (i.e., 5 minutes twice daily) and did not exceed 30 minutes per 
day (i.e., 15 minutes twice daily). Few other studies have reported effects of BAM on SBP at 
6-mo follow-up (Dickinson et al., 2008). In this trial, the effects of TT upon BP were similar 
compared to other in-person interventions involving meditation or other stress reduction 
interventions. For example, in a review of 17 RCTs, Transcendental Meditation was found to 
significantly reduce BP by −5.0 mmHG (Rainforth et al., 2007). Moreover, current results 
suggest TT-guided BAM may yield similar, if not better, average SBP reductions that have 
been observed in lifestyle programs involving EHs and preEHs: exercise (−4.6mmHg), 
weight loss diet (−5 mmHg), low sodium (−3.6 mmHg) and low alcohol intake (−3.8 
mmHg) (Dickinson et al., 2006). Another meta-analysis of 25 RCTs involving relaxation 
meditation and breathing approaches showed large heterogeneity and weak overall 
methodology quality (e.g. reported medications, control groups, short study length, etc.), 
thought results showed an overall −5.5 mmHg reduction in SBP for high BP groups 
(Dickinson et al., 2008). Various other slow breathing studies incorporating in-session 
biofeedback (e.g. EMG, breathing belt feedback) compared to simple slow breathing control 
groups found significant SBP reductions (i.e. intervention ranging −8.4 to −12.8 mmHg 
compared to −2.0 to −7.7 mmHg from controls) in preEHs (D. E. Anderson, McNeely, & 
Windham, 2010; Lin et al., 2012; Wang et al., 2010). Many of these studies used 
approximately 10 sessions, were completed over a 4-5 weeks and used a dosage around 10 
minutes. These studies’ findings are also similar to the reductions found in TT though the 
dose was half of that in the highest TT condition (i.e. 15-min, twice a day), though TT only 
showed graphical feedback after the session was over. Use of personalized HR feedback 
after each TT session may have promoted engagement and increased the efficacy of TT 
across all dosage conditions. Overall, TT showed similar responses to more complicated and 
expensive interventions that require in-person sessions or specialized equipment, which 
underscores the potential value of smartphone-guided BAM for BP reduction.
A significant advantage of TT is the capacity to automatically and objectively assess 
adherence to BAM practice through use of the built-in photoplethysmograph that captured 
pulsatile fingertip HR throughout each TT session. This allows monitoring of the BAM 
sessions, and provides actionable data for personalized motivational feedback when sessions 
are missed or discontinued prematurely. Here, adherence to TT was high across all three 
dosage conditions for the first month, suggesting all participants were engaged in BAM 
practice in the weeks immediately following orientation to the app. This is encouraging 
given that participants were not being paid or otherwise incentivized to complete daily 
practice sessions, particularly in light of evidence that health behavior change apps have 
poor overall uptake and long-term engagement (Krebs & Duncan, 2015).
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Limitations
This study showed a strong effect of BAM using TT to lower BP in adults with preEH, 
though some methodological decisions should be considered when interpreting results. 
Although each session was automatically measured through TT, it was not designed to 
capture the frequency of BAM practice beyond the required session or without TT. 
Additionally, partial completion of individual sessions within a day was not counted towards 
adherence. These limitations could have introduced variability by underestimating the 
duration participants were exposed to BAM. Comments by participants suggested this was 
not a strong concern in the delivery of the intervention. Regardless, the measurement method 
to capture dosage was automatic, quantitative, and stronger than self-report measures.
From a technology use standpoint, the TT application also uses the built-in LED and camera 
for the photoplethysmograph to capture continuous HR data. This uses some additional 
battery power, which may influence users’ ability or decision to use the app consistently in 
their daily lives. Even so, using built-in sensors rather than external wearables reduces 
opportunities for equipment to be lost, broken, or not being appropriately charged and 
eliminates multi-device connection issues (i.e., Bluetooth pairing wearable with 
smartphone).
This study was designed as a quasi-experimental study to determine optimal dosing for the 
TT app, so participants were assigned to one of three dosage conditions for the same 
intervention and not to any non-TT control group. Input from patients and clinics in 
formative research suggested there would be low participation and uptake of in-person BAM 
training. Therefore, no in-person arm was included in this trial, preventing conclusions about 
optimal modalities for teaching and implementing BAM in clinic. Given the lack of these 
comparison groups, results on efficacy should be interpreted with caution. Additionally, a 
finite set of twice daily dosing conditions were examined, and it is possible other dosing 
regimens involving different durations and frequencies of BAM sessions would result in 
similar or better outcomes. Future work may test a broader set of practice regimens. Only 
White and African-American participants were included here, potentially limiting 
generalizability of findings to other racial and ethnic groups. Finally, people taking 
medications that may affect BP were excluded here; future work should evaluate 
acceptability and effects of TT among people with elevated BP due to medication or as an 
adjunct therapeutic approach for people on medications to manage BP.
Future Directions
These results imply a potential use for BAM techniques in the prevention or treatment of EH 
as other in-person TM programs have shown (Barnes & Orme-Johnson, 2012). Findings 
guided design of a clinical trial currently underway to test efficacy of TT on BP and other 
stress-related health outcomes compared to a lifestyle education program in a large sample 
of adults with preEH (ClinicalTrials.gov Identifier: NCT03168789). This study will also 
afford a greater capacity to explore mechanisms underlying TT effects upon BP and other 
outcomes (e.g., perceived stress, physiological stress response). Our team is also developing 
strategies for leveraging the biofeedback and motivational capabilities of TT further improve 
BP outcomes. Additional studies in this line will evaluate staged or multi-phase dosing 
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protocols with respect to BP reductions, adherence, and user acceptability of mHealth 
directed BAM interventions. Further effectiveness trials will compare TT to other stress 
reduction modalities, as well as evaluate uptake, implementation, and clinical outcomes 
among people who independently choose to download TT from publicly accessible app 
stores. The field would benefit from additional research investigating other mHealth 
strategies for delivering BAM for BP reduction, including trials to test the utility of other 
available apps, the integration of a broader array of sensing technologies to track progress, 
and studies in other at-risk populations (e.g., preEH youth).
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Figure 1. 
Participant flow chart following Consolidated Standards of Reporting Trials (CONSORT) 
guidelines.
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Figure 2. 
SBP (in mmHg) changes by Tension Tamer dosage conditions (5, 10, and 15 minutes 2x/
day) at 1-, 3-, and 6-month follow-up. Significance between dosages tested using Tukey-
Kramer adjustments for multiple comparisons. Error bars reported as the standard error of 
the mean.
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Table 2
Tension Tamer effects on SBP, DBP, and HR using intention to treat analysis (n=64)
Unadjusted means (SD) p-value Model 1
p-value
Cohen’s d
SBP Baseline 128.3 (3.6)
SBP Month1 119.2 (5.3) <.001 <.001 1.80
SBP Month 3 119.9 (6.9) <.001 <.001 1.20
SBP Month 6 120.2 (7.4) <.001 <.001 1.13
DBP Baseline 73.1 (7.5)
DBP Month 1 67.3 (7.7) <.001 <.001 1.12
DBP Month 3 68.8 (8.0) .007 .003 .99
DBP Month 6 69.7 (8.0) .054 .034 .70
HR Baseline 75.5 (11.6)
HR Month 1 70.5 (10.9) .015 .01 .67
HR Month 3 73.5 (11.0) .38 .36 .079
HR Month 6 72.6 (10.7) .084 .034 .44
Standard deviation: SD, systolic blood pressure: SBP (in mmHg), diastolic blood pressure: DBP (in mmHg), heart rate: HR (bpm). Mixed 
Modeling was used to test statistical significance for each follow-up time point compared to baseline. Model 1: adjusted for age, race, gender; 
Model 2: adjusted for all covariates in Model 1 and physical activity (sweat index). Effect size: Cohen’s d = (Baseline - follow-up month)/SD, 
Cohen’s d conventions: (small .2, medium .5, large .8).
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Table 4a
Mean adherence to Tension Tamer prescription by dose
Dose (in min 2x day)
Month 5
(n = 23)
10
(n = 19)
15
(n = 22)
p-value
1 75.7 ± 29.0 75.8 ± 23.3 73.0 ± 23.3 .77
2 77.2 ± 21.2 83.6 ± 15.3 67.3 ± 23.6 .05*
3 74.7 ± 20.2 76.0 ± 23.2 56.4 ± 27.4 .018*
4 71.5 ± 29.1 69.9 ± 26.5 55.7 ± 27.3 .15
5 76.4 ± 19.9 70.5 ± 26.4 55.1 ± 27.8 .037*
6 78.3 ± 17.7 73.3 ± 21.5 48.4 ± 28.9 .001*
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Table 4b
Proportion of participants meeting 75% of Tension Tamer as randomized
Dose (in min 2x day)
Month 5
(n=21)
10
(n=18)
15
(n=20)
p-value
1 66.7% (14/21) 61.1% (11/18) 70.0% (14/20) .93
2 65.0% (13/20) 88.2% (15/17) 45.0% (9/20) .023*
3 60.0% (12/20) 70.6% (12/17) 70.0% (14/20) .034*
4 55.0% (11/20) 47.1% (8/17) 36.8% (7/19) .52
5 58.8% (10/17) 53.3% (8/15) 29.4% (5/17) .19
6 76.5% (13/17) 50.0% (7/14) 20.0% (3/15) .006*
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Table 4c
Proportion of participants meeting 75% of Tension Tamer with intention to treat
Dose (in min 2x day)
Month 5
(n=23)
10
(n=19)
15
(n=22)
p-value
1 60.9% (14/23) 57.9% (11/19) 63.6% (14/22) .84
2 56.5% (13/23) 78.9% (15/19) 40.9% (9/22) .023*
3 52.2% (12/23) 63.2% (12/19) 27.3% (6/22) .034*
4 47.8% (11/23) 42.1% (8/19) 31.8% (7/22) .44
5 43.5% (10/23) 42.1% (8/19) 22.7% (5/22) .22
6 56.5% (13/23) 36.8% (7/19) 13.6% (3/22) .006*
Comparisons of mean (Table 4a.) by dosage (5, 10, and 15 min, twice daily) and study month using mixed modeling analysis. Tables 4b and 4c 
show proportion of participants meeting at least 75% adherence with p values calculated using Chi-square tests. Adherence was measured by 
calculating % of completed sessions divided by the expected sessions for the study month via automated recorded data capture by Tension Tamer 
app uploaded to trial servers.
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